ES2180258T3 - Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes. - Google Patents

Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.

Info

Publication number
ES2180258T3
ES2180258T3 ES99401645T ES99401645T ES2180258T3 ES 2180258 T3 ES2180258 T3 ES 2180258T3 ES 99401645 T ES99401645 T ES 99401645T ES 99401645 T ES99401645 T ES 99401645T ES 2180258 T3 ES2180258 T3 ES 2180258T3
Authority
ES
Spain
Prior art keywords
expression
improve
adenoviral
open reading
genes expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99401645T
Other languages
English (en)
Inventor
Majid Mehtali
Monika Lusky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of ES2180258T3 publication Critical patent/ES2180258T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)

Abstract

Se describen vectores adenovirales recombinantes que retienen suficientes secuencias E4 para mejorar la expresión y/o persistencia de la expresión de un gen de interés. Además la invención describe el uso de un polinucleótido que codifica uno o más ORF(s) de la región E4 de un adenovirus seleccionado entre ORF1, ORF2, ORF3, ORF4, ORF3/4, ORF6/7, ORF6 Y ORF7 tomados individualmente o en combinación para mejorar la expresión y/o la persistencia de la expresión de un gen de interés operablemente unido a elementos reguladores e insertado dentro de un vector de expresión. Finalmente, se describen una célula anfitriona, una composición, una partícula viral infecciosa que comprende dicho polinucleótido o vector adenoviral, un procedimiento para preparar dicha partícula viral así como su uso terapéutico.
ES99401645T 1998-07-07 1999-07-01 Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes. Expired - Lifetime ES2180258T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98401722 1998-07-07
EP98402825 1998-11-13

Publications (1)

Publication Number Publication Date
ES2180258T3 true ES2180258T3 (es) 2003-02-01

Family

ID=26151663

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99401645T Expired - Lifetime ES2180258T3 (es) 1998-07-07 1999-07-01 Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
ES01124236T Expired - Lifetime ES2210081T3 (es) 1998-07-07 1999-07-01 Utilizacion de los marcos de lectura de la region e4 para la mejora de la expresion de genes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01124236T Expired - Lifetime ES2210081T3 (es) 1998-07-07 1999-07-01 Utilizacion de los marcos de lectura de la region e4 para la mejora de la expresion de genes.

Country Status (11)

Country Link
US (1) US6475480B1 (es)
EP (2) EP0974668B1 (es)
JP (1) JP2000106875A (es)
AT (2) ATE225400T1 (es)
AU (1) AU756607B2 (es)
CA (1) CA2276791A1 (es)
DE (2) DE69914382T2 (es)
DK (2) DK0974668T3 (es)
ES (2) ES2180258T3 (es)
HK (1) HK1043390A1 (es)
PT (2) PT974668E (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225113B1 (en) * 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
EP1301612A2 (en) * 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
US20040106194A1 (en) * 2002-08-22 2004-06-03 Bett Andrew J. Methods for propagating adenovirus and virus produced thereby
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
EP1831382B1 (en) * 2004-12-31 2023-01-18 Per Sonne Holm Method for reversing multiple resistance in animal cells
WO2008073893A2 (en) * 2006-12-08 2008-06-19 Adv Technologies Llc Methods for producing an adenovirus type 5 gene transfer vector
US8465732B2 (en) 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
KR101667094B1 (ko) 2010-08-16 2016-10-17 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 항암 아데노바이러스
KR101522341B1 (ko) * 2012-10-02 2015-05-21 국립암센터 신규한 조건부-복제 가능 아데노바이러스 및 그의 제조 방법
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3612556B8 (en) 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
CN110656090B (zh) * 2019-10-28 2023-06-30 嘉兴安宇生物科技有限公司 一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用
CN110714027A (zh) * 2019-10-28 2020-01-21 嘉铭(固安)生物科技有限公司 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
WO2022007800A1 (zh) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 一种非洲猪瘟的重组腺病毒疫苗及其构建方法
JP7555643B2 (ja) * 2021-01-21 2024-09-25 株式会社 セリッド 複製能のあるアデノウイルスを包含しない新規アデノウイルスベクター、およびこれの使用
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP0673431A1 (en) * 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
WO1998021350A1 (en) * 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence

Also Published As

Publication number Publication date
AU3800999A (en) 2000-06-08
DE69903229T2 (de) 2003-06-26
DK1199368T3 (da) 2004-04-13
DE69903229D1 (de) 2002-11-07
US6475480B1 (en) 2002-11-05
DE69914382D1 (de) 2004-02-26
HK1043390A1 (en) 2002-09-13
EP0974668A1 (en) 2000-01-26
ES2210081T3 (es) 2004-07-01
EP1199368B1 (en) 2004-01-21
ATE225400T1 (de) 2002-10-15
ATE258228T1 (de) 2004-02-15
PT974668E (pt) 2003-01-31
EP0974668B1 (en) 2002-10-02
PT1199368E (pt) 2004-04-30
DK0974668T3 (da) 2002-11-11
JP2000106875A (ja) 2000-04-18
DE69914382T2 (de) 2004-11-04
AU756607B2 (en) 2003-01-16
EP1199368A2 (en) 2002-04-24
CA2276791A1 (en) 2000-01-07
EP1199368A3 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
PT1199368E (pt) Utilizacao de blocos de leitura da regiao e4 adenoviral para melhorar a expressao de um gene relevante
IL234063A (en) Adenovirus containing capsid aavrh.34 and a heterologous gene, its preparation and preparations containing it
IL199126A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters.
EP0851769A4 (en) Gene therapy using ovine adenoviral vectors
SI1496944T1 (sl) Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov
DE69936104D1 (de) Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
EP2281877A3 (en) Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
CY1110982T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
DE69535467D1 (de) Faktor aus pigmentiertem epithel (pedf) charakterisierung, genomische organisation und sequenz des pedf gens
ES2337768T3 (es) Metodo para purificar adenovirus.
WO2005052143A3 (de) Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
WO1998055639A3 (fr) Vecteurs adenoviraux recombinants comprenant une sequence d'epissage
EP1203819A3 (en) Anti-inflammatory vectors
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
EP0752888A4 (en) NUCLEOTID AMINO ACID SEQUENCES OF THE HERPEVIRUS gB, gC AND gD FROM DOG AND THEIR USE
JPH0773500B1 (es)
WO2006116267A3 (en) Cell-specific molecule and method for importing dna into osteoblast nuclei
EP0774002A4 (en) DNA CODING FOR THE SHEEP ADENOVIRUS (OAV287) AND THEIR USE AS A VIRAL VECTOR
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
WO2002008395A3 (en) Putative human methyltransferase family member and uses thereof
CHEN et al. STUDY OF GENES DIFFERENTIALLY EXPRESSED IN CD34~+ CELLS FROM G-CSF-MOBILIZED PERIPHERAL BLOOD AND BONE MARROW USING THE TECHNIQUE OF SUPPRESSION SUBTRACTIVE HYBRIDIZATION
ZHOU et al. DNA microarray analysis of genome dynamics in Yersinia pestis: insight into bacterial genome microevolution and niche adaptation
MA et al. Expression of Mage-A1, A2, A3 in breast cancer tissue and breast cancer cell lines
SUN et al. Adeno-associated Virus Serotype 2 Mediated Transduction and Expression of The Human?-Globin Gene in Human Early Fetal Liver Hematopoietic Cells
CHE et al. Study of E-cadherin Antisense Oligodeoxynucleotide on Invasive Ability of Tumor Cells